A retrospective study to evaluate de novo use of Everolimus in late onset cytomegalovirus primary diseases after withdrawal of antiviral prophylaxis in kidney transplant patients

Trial Profile

A retrospective study to evaluate de novo use of Everolimus in late onset cytomegalovirus primary diseases after withdrawal of antiviral prophylaxis in kidney transplant patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 May 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Cytomegalovirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 May 2017 New trial record
    • 03 May 2017 Results presented at the 2017 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top